Table 2.
Clinical and Laboratory Characteristics of the Study Population in the Longitudinal Analysis According to Quartile Distribution of Neutrophil Cell Count
| Neutrophil Cell Count | P Value* | ||||
|---|---|---|---|---|---|
| <3180/µL | 3180–3929/µL | 3930–4799/µL | ≥4800/µL | ||
| Total mortality, % | 9.8 | 21.8 | 18.5 | 27.5 | 6.1×10−5 |
| Cardiovascular mortality, % | 5.2 | 16.6 | 14.4 | 19.7 | 2.9×10−4 |
| Age, y | 61.3±9.2 | 61.0±9.8 | 62.7±9.5 | 62.0±10.1 | NS |
| Male sex, % | 75.5 | 80.1 | 81.5 | 83.6 | 0.040 |
| BMI, kg/m2 | 26.7±3.2 | 26.8±3.9 | 26.7±3.3 | 26.5±3.7 | NS |
| Smoker, % | 59.4 | 69.7 | 71.0 | 70.7 | 0.017 |
| Hypertension, % | 67.5 | 66.0 | 65.2 | 66.3 | NS |
| Diabetes mellitus, % | 11.6 | 15.9 | 21.6 | 17.3 | NS |
| Myocardial infarction, % | 57.9 | 57.8 | 56.2 | 63.7 | NS |
| eGFR, mL/min | 75.6±16.1 | 73.5±17.3 | 74.5±18.3 | 73.2±22.5 | NS |
| Total cholesterol, mmol/L | 5.56±1.17 | 5.60±1.18 | 5.58±1.22 | 5.30±1.16 | 0.027 |
| LDL cholesterol, mmol/L | 3.74±1.00 | 3.72±1.06 | 3.76±1.09 | 3.66±0.92 | NS |
| HDL cholesterol, mmol/L | 1.24±0.31 | 1.17±0.32 | 1.22±0.30 | 1.12±0.31 | 0.004 |
| Triglycerides, mmol/L | 1.60 (1.49–2.62) | 1.76 (1.66–1.86) | 1.70 (1.60–1.80) | 1.69 (1.59–1.80) | NS |
| hs‐CRP, mg/L | 2.23 (1.90–2.62) | 2.98 (2.52–3.51) | 3.94 (3.29–4.72) | 7.04 (5.89–8.41) | 6.2×10−12 |
| D‐dimer, mcg/mL † | 0.53 (0.46–0.61) | 0.58 (0.51–0.67) | 0.58 (0.49–0.68) | 0.73 (0.62–0.85) | 0.004 |
| CXCL12, pg/mL ‡ | 2198 (2116–2282) | 2234 (2165–2306) | 2284 (2206–2364) | 2234 (2143–2330) | NS |
| Carriership of prothrombin 20210 A allele, % § | 4.4 | 3.4 | 5.5 | 8.0 | NS |
BMI indicates body mass index; CXCL12, C‐X‐C motif chemokine 12; eGFR, estimated glomerular filtration rate; HDL, high‐density lipoprotein; hs‐CRP, high‐sensitivity C‐reactive protein; and LDL, low‐density lipoprotein.
*
By ANOVA with polynomial contrasts for linear trend or by χ2 for linear trend, when appropriate.
†
D‐dimer data were available for 435 out of 823 subjects (52.9%).
‡
CXCL12 data were available for 530 out of 823 subjects (64.4%).
§
Prothrombin G20210A genotype data were available for 717 out of 823 subjects (87.1%).